hemophilia

Raleigh-based GeneVentiv Therapeutics awarded $2.5 million SBIR Grant to advance gene therapy for all hemophilias

Posted by WRAL News | Apr 16, 2024

Startup Spotlight: UNC-linked startup is giving hope to those with hemophilia

Posted by WRAL TechWire | Feb 8, 2022

GeneVentiv Therapeutics is developing the first universal gene therapy for all types of hemophilia, including the most difficult cases. Let’s take a look.

Sanofi acquiring US biotech Bioverative for $11.6B + Sanofi history of deals

Posted by WRAL TechWire | Jan 22, 2018

Drugmaker Sanofi is buying U.S. hemophilia specialist Bioverativ for $11.6 billion in a deal that Sanofi says will boost its profile for fighting rare diseases.